Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 1/20 | 0.52 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16507018 | 1.00 | LPAR1 (0.52) | LPAR1LPAR5KDM4ESMN1; SMN2TSHR | |
| SCHEMBL2473263 | 0.86 | LPAR1 (0.51) | LPAR1LPAR5SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL2473260 | 0.86 | LPAR1 (0.51) | LPAR1LPAR5SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL16507227 | 0.84 | ALDH1A1 (0.57) | LPAR1LPAR5KDM4ESMN1; SMN2TSHR | |
| SCHEMBL2166026 | 0.84 | KDM4E (0.54) | KDM4ESMN1; SMN2TSHRPOLBALDH1A1 | |
| SCHEMBL4441490 | 0.82 | TSHR (0.54) | KDM4ESMN1; SMN2TSHRPOLBALDH1A1 | |
| SCHEMBL16506413 | 0.81 | LPAR1 (0.57) | LPAR1LPAR5HPGD | |
| SCHEMBL10148355 | 0.81 | LPAR1 (0.57) | LPAR1LPAR5HPGD | |
| SCHEMBL10148021 | 0.81 | RAB9A (0.49) | LPAR1LPAR5KDM4ESMN1; SMN2TSHR | |
| SCHEMBL10148089 | 0.80 | POLB (0.52) | POLBALDH1A1KMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | LPAR1 1629/4885LPAR5 2217/4885KDM4E 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.